3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
5
Triple Negative Breast Neoplasms
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Glioblastoma
2
Thrombocythemia, Essential
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Renal Insufficiency
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pathologic Complete Response
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Myelodysplastic-Myeloproliferative Diseases
1
Melanoma
1
Lung Neoplasms
1
Liver Failure
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Magnetic Resonance Spectroscopy
8
X-Rays
6
Specimen Handling
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
5
Biopsy
4
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
lutetium Lu 177 dotatate
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
LY3023414
2
pembrolizumab
1
neratinib
1
cemiplimab
1
brigatinib
1
Watchful Waiting
1
Vincristine
1
Vemurafenib
1
Temozolomide
1
Radiotherapy, Conformal
1
Radiotherapy
1
Radiation
1
Platinum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Ependymoma
×
veliparib
×
90 days
×
Clear all
No trials found.